[Featured Stock] GI Innovation Rises on Technology Transfer from Japanese Pharmaceutical Company
G.I. Innovation is on the rise following news that it has licensed its allergy treatment 'GI-301' to a Japanese pharmaceutical company.
As of 9:59 AM on the 17th, G.I. Innovation was trading at 23,550 KRW, up 1.51% from the previous trading day.
The day before, G.I. Innovation signed a contract with Maruho, a Japanese pharmaceutical company specializing in dermatological diseases, receiving a non-refundable signing fee, as well as milestone payments for clinical development, commercialization, and sales commissions. Maruho will lead the clinical trials and commercialization of GI-301 in Japan. The contract is valued at approximately 298 billion KRW.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Woman Experiences Eye Protrusion After 20 Years of Contraceptive Injections, Plans Lawsuit Against Major Pharmaceutical Company
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Earlier, Japanese Prime Minister Fumio Kishida held a cabinet meeting at the Tokyo Prime Minister's Office in May, declaring a "war on pollen allergy" with the goal of reducing pollen levels to half of the current amount within 30 years.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
